CELLERITAS
DEAD

Add to watchlist:

No watchlists yet
View on USPTO

CELLERITAS Trademark

Serial Number: 97697528

CELLERITAS is a trademark filed by CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC on November 30, 2022. The trademark is classified under Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC (19 trademarks)

411 SWEDELAND ROAD
KING OF PRUSSIA, PA 19406

Entity Type: 16

Trademark Details

Filing Date

November 30, 2022

Registration Date

Not Registered

Published for Opposition

October 17, 2023

Goods & Services

Research and development services in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services, namely, production of cell lines for others using lentivirus technology; scientific research and technical research services relating to producing, assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producing, assaying, and purifying adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for others, namely, cGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and manufacturing; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; material testing; product quality testing; scientific laboratory services; scientific research; research and development in the field of gene therapy acceleration, vector genome copy titers, droplet digital polymerase chain reaction (PCR) and digital polymerase chain reaction (PCR), mass spectrometry, capsid characterization, bioassays, plasmid DNA, and analytics testing in the field of genes and gene therapy

Manufacturing services for others in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals, plasmid DNA production; manufacturing services for others in the fields of mammalian cell banks, plasmids, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; manufacturing process consulting

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jan 12, 2026 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jan 12, 2026 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 17, 2025 EXRA
SOU EXTENSION 3 GRANTED
Apr 17, 2025 EX3G
SOU EXTENSION 3 FILED
Apr 16, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Apr 16, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 21, 2024 EXRA
SOU EXTENSION 2 GRANTED
Oct 21, 2024 EX2G
SOU EXTENSION 2 FILED
Oct 21, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Oct 21, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 10, 2024 EXRA
SOU EXTENSION 1 GRANTED
May 9, 2024 EX1G
SOU EXTENSION 1 FILED
May 9, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
May 9, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 12, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 17, 2023 NPUB
PUBLISHED FOR OPPOSITION
Oct 17, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 27, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 14, 2023 CNSA
ASSIGNED TO EXAMINER
Sep 9, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 22, 2022 NWOS
NEW APPLICATION ENTERED
Dec 3, 2022 NWAP